Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.

The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Here are the five things you need to know, including Lyra's good news, Sanofi's acquisition, Mass. biotech jobs, inside Market Basket's board, AI, and hiring entry-level jobs.

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

The French drugmaker has acquired Blueprint Medicines Corporation following its sale of health consumer brand Opella.

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...